The potential toxic effects of bivalirudin (an anticoagulant) were evaluated in this intravenous infusion study in Sprague-Dawley rats. Bivalirudin was administered over a 24-hour period by continuous intravenous infusion to six groups of rats. Dose levels of 100, 500, and 2000 mg/kg/24 h were selected for the low-, mid-, and high-dose groups. Three bivalirudin-treated groups of 12 males and 12 females each were designated for toxicology assessment. Six animals/sex/group were euthanized at the completion of 24hour infusion, and the remaining animals were assigned to a 14day recovery period. Three additional groups of 10 rats/sex/group were designated for toxicokinetic assessment. This study included a saline control group and a vehicle control group. No bivalirudinrelated toxicity was noted. There were no treatment-related effects on clinical pathology parameters. No definitive test articlerelated macroscopic, organ weight, or microscopic changes were identified. Three animals in the 500-mg/kg/24 h group, and 7 animals in the 2000-mg/kg/24 h group in the toxicokinetic assessment phase of the study were found dead or euthanized in extremis (following blood sampling). The concurrent clinical signs suggest that the animals hemorrhaged, which is consistent with the pharmacological action of bivalirudin. The extent of systemic exposure was similar in male and female rats, indicating a lack of a sex-related difference. Plasma concentrations of bivalirudin appeared to be linear and dose independent. Based on the results of this study, the no-observed-adverse-effect level (NOAEL) for bivalirudin, administered to rats via intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h. However, the known pharmacological properties of bivalirudin could result in hemorrhage in the presence of an appropriate challenge (e.g., blood collection).
Bivalirudin (Angiomax, The Medicines Company, Parsippany, NJ) is a novel synthetic 20-amino acid peptide designed from the protein, hirudin, a natural protein with anticoagulant properties first isolated from the common leech, Hirudo medicinalis. Bivalirudin consists of the NH2-terminal tetrapeptide sequence and the cationic HOOC-terminal dodecapeptide sequence from the hirudin molecule, bridged together with a tetraglycine spacer. Bivalirudin has projected utility in the prevention of postsurgical thrombosis as well as in the prevention of clotting during heart-lung bypass and renal dialysis. These clinical applications tend to result in acute or short-term human exposure. Although short-term, repeated-dose toxicity had been examined, there were concerns as to whether these studies would adequately predict human toxicity under maximal short-term exposure conditions. The objective of the study was to evaluate the possible toxic effects of bivalirudin when administered to rats intravenously at high dosages by infusion over a 24-hour period, and recovery from these toxic effects, should any be identified. The low dose for this study was selected based on a theoretical clinical maximum dose of 11 mg/kg/4 h, which could accidentally result in an exposure of 66 mg/kg over a 24-hour period. The high dose was based on 2× the high dose used in a previous 14-day infusion study with bivalirudin (Gamba-Vitalo 1994) . The mid dose was the approximate geometric mean of the low and high doses. In this study, the toxicokinetic behavior of bivalirudin at these high dosages was also examined. The selected route of administration for bivalirudin was continuous intravenous infusion via an indwelling cannula, because this is the route of administration used in clinical practice.
The animal model, the Hsd:Sprague-Dawley SD rat, is recognized as appropriate for acute toxicity studies and is a widely used strain for which significant historical control data are available. In addition, the age and weight ranges of the animals used for this study are recognized as appropriate for continuous intravenous infusion studies. Bivalirudin 2000 40 50 10 10 a 6 animals/sex/group in the toxicology groups were necropsied at conclusion of infusion; remaining 6 animals/sex/group were necropsied following a 14-day recovery period. group, was manufactured by Baxter Healthcare Corporation, Deerfield, Illinois. The vehicle control article, used to dose animals in the vehicle control group, was 2.64% mannitol in deionized water. In the preparation of the test article formulations, a solution of 0.5 N sodium hydroxide (NaOH) in 2.64% mannitol was prepared and used for pH correction of the test article formulation. The sodium hydroxide and d-mannitol USP were obtained from Sigma Chemical, St. Louis, Missouri.
Preparation of Dosing Solutions
Aseptic techniques were used during the preparation of the test and control articles. Appropriate procedures were performed within a Nuaire hood (Nuaire, Inc., Plymouth, MN).
The vehicle control solution, 2.64% mannitol, was prepared by quantitatively transferring the appropriate amount of d-mannitol, USP, to a calibrated storage container at least halffilled with stirring deionized water. The solution was stirred until visually clear. Additional deionized water was added to bring the solution to volume. The 2.64% mannitol solution was stored refrigerated. For the vehicle control group, the solution was filtered through a 0.22-µm Durapore membrane filter (Fisher Scientific, Florence, KY) and transferred to a sterile septum bottle with a cap for the day of infusion.
For bivalirudin (test article) formulations the appropriate amount of the vehicle control (2.64% mannitol) solution was transferred into calibrated storage containers for each group. The solutions were stirred in a water bath maintained at 2 • C to 8 • C. The appropriate amount of bivalirudin for each group was weighed into tared weigh boats and quantitatively transferred into the stirring 2.64% mannitol solution, and the formulations were stirred until the bivalirudin was dissolved. An equimolar amount of the NaOH in 2.64% mannitol solution was quickly added. As this addition caused the bivalirudin to precipitate out of solution briefly, the formulations were stirred at high speed until the bivalirudin redissolved. The pH was measured and adjusted, as necessary, to 5.1 to 5.5 using the 0.5 N NaOH in 2.64% mannitol solution. This pH appeared to give the best balance between the solubility of the test article and the need to keep the solution as nonirritating. A sufficient amount of 2.64% mannitol was added to bring the formulation to volume. Each formulation was then sterile-filtered through a 0.22-µm Durapore membrane filter into labeled septum bottles with caps. The test article formulations were prepared once (on the day of infusion), maintained at room temperature, and protected from light during the sampling, dispensation, and dosing procedures.
Formulation Sampling and Analyses
Duplicate samples (5 ml) from the saline control, vehicle control, and each bivalirudin formulation were collected on the day of formulation. All samples were stored frozen until transfer to the Analytical Chemistry Department, WIL Research Laboratories, for concentration analysis. Mean percentages of target concentrations for the dosing formulations ranged from 105% to 110%.
Animal Receipt, Acclimation, and Husbandry
One hundred fourteen male and 111 female Hsd:Sprague-Dawley SD rats in apparent good health were received from Harlan Sprague Dawley, Madison, Wisconsin. They were approximately 9 weeks old at receipt. The animals were examined by a qualified technician on the day of receipt and weighed the following day. Body weights ranged from 154 to 282 g for the males and from 207 to 247 g for the females. Each animal was uniquely identified using a Monel metal eartag displaying the permanent animal number. All animals were housed for an acclimation period of at least 20 days prior to initiation of infusion, and all animals received an acclimation period of at least 5 days prior to the surgical placement of the indwelling catheter; observations were made twice daily for mortality and general changes in appearance and behavior.
Detailed physical examinations were conducted and body weights were recorded during the week prior to the initiation of infusion (week −1) to ensure the use of healthy animals. Additionally, a body weight was recorded for each animal on the day of surgery. Except where warranted, pretreatment data are not presented in the manuscript.
Upon arrival, all animals were housed individually in sanitized wire-mesh cages suspended above cage-board. All animals were housed in an environmentally controlled room throughout the acclimation period and during the study. Controls were set to maintain a temperature of 72 • F ± 4 • F (22 • C ± 2 • C) and a relative humidity of 30% to 70%. Room temperature and relative humidity were recorded daily. Light timers were set to provide a 12-hour light/12-hour dark photoperiod, except when the lights were turned on to collect toxicokinetic samples.
The diet used in this study, PMI Nutrition International Certified Rodent LabDiet 5002, is a certified feed with appropriate analyses performed by the manufacturer. The results of the feed and water analyses are maintained at WIL Research Laboratories. Municipal water supplying the facility is sampled and analyzed for contaminants according to standard operating procedures. Reverse osmosis-treated (on-site) drinking water, delivered by an automatic watering system, and the basal diet were provided ad libitum throughout the study period.
Assignment of Animals to Treatment Groups
Randomization into study groups was performed following recovery from surgery. The condition of the cannulae was evaluated prior to randomization. On the day prior to initiation of bivalirudin infusion for the toxicology groups, all available rats were weighed and examined in detail for physical abnormalities. From those judged suitable for testing, the requisite number of animals was selected for use in the toxicology phase of the study using a computerized randomization procedure. A printout containing the animal numbers, corresponding body weights, and individual group assignments was generated based on body weight stratification in a block design. Body weights at randomization were within ±20% of the mean for each sex. Sixty male and 60 female rats were assigned to the toxicology assessment groups. Each control and test article-treated group (groups 1 to 5) in this designation consisted of 12 animals/sex. On the day of randomization, body weights ranged from 256 to 352 g for the males and 218 to 273 g for the females. Animals not assigned to the toxicology phase of the study were used for the toxicokinetic phase. Thirty male and 30 female rats were assigned to the toxicokinetic assessment phase of the study. Each group (groups 3A to 5A) in this designation consisted of 10 animals/sex. Body weights at the initiation of infusion ranged from 271 to 358 g for the males and 234 to 271 g for the females. The selected animals in both assessment designations were approximately 12 weeks old at the initiation of infusion.
Animal Preparation
One hundred animals of each sex were surgically prepared for this study. Surgeries were performed over a 5-day period. The animals were given an acclimation period of at least 5 days prior to surgery and a recovery period of approximately 2 weeks prior to initiation of infusion. All animals were treated with penicillin (0.1 ml/animal, 300,000 IU/ml) on each of the 2 days prior to surgery. Just prior to surgery, selected animals were anesthetized with an intramuscular injection of ketamine HCl and xylazine (4:1 mixture, 1 ml/kg). Salve was applied to both eyes of all animals undergoing surgery. The incision and exteriorization sites were shaved and cleaned with antiseptics (Betadine and alcohol). Each animal was draped with the left inguinal region exposed for surgery and a small subcutaneous incision was made. The left femoral vein was isolated. A small incision was made in the vein, and a medical grade silastic cannula (0.020 inch inner diameter by 0.037 inch outer diameter) was inserted to approximately the level of the renal vein. The cannula was then secured with appropriate suture material to the abdominal wall and the incision was closed with 9-mm autoclips. The cannula was exteriorized via a trocar between the shoulder blades. Although not required by protocol, the ventral incision and the dorsal exteriorization site on each animal were flushed with a solution of penicillin-G.
The exteriorized cannula was fed through and housed within a stainless steel, flexible tether that was attached to a swivel. The swivel was attached to a clamp outside each animal's cage and allowed complete freedom of movement to the animal. The entire tether-swivel system was attached to a jacket that was then placed on the animal and fastened with Velcro. An appropriate length of polyurethane tubing connected the cannula (housed in the tether-swivel unit) to the infusion syringe, which was covered with foil for light protection.
Immediately after closure of the surgical sites, a topical antibiotic (Nolvasan) was applied to both the surgical and dorsal exteriorization sites. The animals were then treated with penicillin (0.1 ml/animal, 300,000 IU/ml). After surgery and until initiation of the test or control article infusions, the animals were maintained on a constant infusion of 0.9% sodium chloride for injection, USP, delivered at approximately 0.5 ml/h using a Razel syringe pump (Razel Scientific Instruments, Stamford, CT). Surgically prepared animals not assigned to the study were maintained in a similar manner until no longer needed, then euthanized and discarded.
Infusion
Prior to placement of the dosing syringe on the infusion pump, each infusion apparatus was prefilled with approximately 0.6 ml (the calculated capacity of the infusion system) of the appropriate control or test article solution. The infusion apparatus and dosing syringe were covered with foil for light protection during the infusion period. Each pump was adjusted to deliver the exact volume of test or control article to achieve the appropriate mg/kg/h dose over an approximate 24-hour period. Individual volumes were based on the body weight recorded on the day prior to the initiation of bivalirudin infusion. Each test article syringe was weighed before and after the infusion period in order to verify the individual dose received. Mean 24-hour dose ranges represent an overall mean percent of target of approximately 102% for all test article-infused toxicology assessment groups and 101% for all toxicokinetic assessment groups.
At the conclusion of the 24-hour infusion period, the dosing syringes were removed and each infusion apparatus was flushed with 0.6 ml of 0.9% sodium chloride for injection, USP, to ensure administration of any remaining control or test article. Each cannula was then tied off at the exteriorization site. When a cannula was tied off, great care was taken to prevent it from pulling out of the vein. The jacket and tether systems were removed and the animals were placed in a standard cage bank until the scheduled necropsy.
Clinical Observations and Survival
All animals were observed twice daily, once in the morning and once in the afternoon, for mortality and moribundity. Clin-ical observations (toxicology groups only) were performed just prior to the initiation and the completion of the 24-hour infusion period, and at 1 to 2 hours following the completion of infusion (designated 1-hour post infusion for reporting purposes). All significant findings were recorded. During the nondosing (recovery) period, clinical observations were performed once daily. Detailed physical examinations (toxicology groups only) were conducted prior to the first surgery day, at randomization, and just prior to the scheduled necropsies.
Body Weights
Individual body weights were recorded on days −7, −1, 6, and 13, as appropriate. Individual body weights were corrected for the added weight of the cannula, infusion lines, jacket, and tether system. For the toxicology assessment phase animals, mean body weight changes were calculated for each interval. Final body weights were recorded prior to the scheduled primary and recovery necropsies (days 1 and 15, respectively).
Food Consumption (Toxicology Groups Only)
Individual food consumption was recorded weekly, beginning approximately 1 week prior to test article administration. Food intake was calculated as g/animal/day.
Clinical Pathology (Toxicology Groups Only)
The clinical pathology parameters examined are presented in Table 2 . Blood and urine samples for clinical pathology evaluations (hematology, serum chemistry, and urinalysis) were collected from all animals at the scheduled necropsies. Blood samples were collected from the abdominal aorta of unfasted animals (under Metofane anesthesia) at the time of necropsy. Urine was collected overnight using metabolism cages. Sodium heparin was the anticoagulant used for hematological samples and sodium citrate was the anticoagulant used on samples collected for coagulation factor (prothrombin time [PT] and activated partial thromboplastin time [APTT]) determinations.
Clinical chemistry parameters were determined using a Hitachi Model 911 chemistry analyzer using application codes provided by the manufacturer and reagents provided by Boehringer Mannheim (Indianapolis, IN) . Hematological parameters were determined using an Abbot CELL DYN 3500 according to the manufacturer's operator's manual. Coagulation parameters were determined using an Automated Coagulation Analyzer-Electra 1400C (Medical Laboratory Automation), according to methods provided by the manufacturer. Standard urinalysis parameters were determined using Bayer reagent strips that were read using a CLINITEK 200+ Urine Chemistry Analyzer. Specific gravity was measured using an ATAGO Urine Specific Gravity Refractometer manufactured by NSG Pression Cells. Urinary sediment was separated by centrifugation and examined microscopically using routine methods. 
Toxicokinetics (Toxicokinetic Groups Only)
Blood samples (approximately 0.5 ml each) for toxicokinetic determination were collected into tubes containing sodium heparin at 1.5, 3, 6, 12, 24, and 48 hours after the start of infusion. At each time point, blood was collected from the retro-orbital sinus of 3 animals/sex/group. The animals were anesthetized with Metofane. Time points were rotated among the animals in each group to ensure that no animal was sampled more than twice in a 24-hour period. The same 3 animals/sex/group were sampled at the 1.5-and 12-hour collection times, a different 3 animals/sex/group at the 3-and 24-hour collection times, and a third set of 3 animals/sex/group at the 6-and 48-hour collection times, if possible. The study design required only 9 rats/sex/toxicokinetic group; thus, each toxicokinetic group had 1 spare rat/sex. If not sampled, the rat was euthanized and discarded. All surviving toxicokinetic group animals were euthanized without necropsy following blood collection.
Plasma was prepared by centrifugation and stored frozen at approximately −70 • C. The frozen samples were shipped on dry ice via overnight carrier to Quintiles Scotland, Riccarton, Edinburgh, UK, for analysis. Plasma concentrations of bivalirudin were determined using a competitive enzyme immunoassay (EIA) procedure.
Macroscopic Examination (Toxicology Groups)
A complete necropsy was conducted on all animals. At the scheduled necropsies, all rats were euthanized by metofaneinduced narcosis followed by exsanguination. On day 1, all necropsies were performed within approximately 3 to 4 hours of the termination of the infusion period. The necropsy included examination of the external surface, all orifices, and the cranial, thoracic, abdominal, and pelvic cavities including viscera. At the time of necropsy, the tissues and organs (Table 3) were collected and placed in 10% neutral-buffered formalin. Selected organs were also weighed. Paired organs were weighed together. Organ-to-final-body-weight and organ-to-brain-weight ratios were calculated.
Histopathologic Procedures and Microscopic Examination
After fixation, the tissues listed in Table 3 were trimmed as described by Thompson (1966) . Trimmed specimens were placed in appropriately labeled and numbered cassettes. The fixed tissue samples were processed into paraffin blocks. The labeled paraffin blocks were sectioned at 5 to 8 µm and the paraffin ribbons of the sectioned tissue were placed on clean glass microscope slides, labeled with the appropriate study, animal, group, and cassette numbers. Upon completion of staining with hematoxylin and eosin (American Registry of Pathology 1968), cover slips were placed on the slides.
Microscopic examinations were performed on all tissues listed in Table 3 from animals found dead, and those from the saline control, vehicle control, and 2000-mg/kg/24 h groups at both scheduled necropsies (groups 1, 2, and 5, respectively). In addition, the infusion site (vena cava past the cannula tip), liver, lungs, kidneys, and any gross lesions were examined from all animals in 100-and 500-mg/kg/24 h groups (groups 3 and 4, respectively).
Statistical Methods (Toxicology Groups)
All analyses were conducted using two-tailed tests for significance levels of 5% and 1% comparing both control groups to the treated groups and to each other by sex. All means are presented with standard deviations (SD) and the number of sampling units (N ) used to calculate the means. Body weight, body weight change, food consumption, clinical pathology, and absolute and relative organ weight values were subjected to a one-way analysis of variance (ANOVA) (BMDP 1979) , followed by Dunnett's test (Dunnett 1964) . Clinical laboratory values for cell types that occur at a low incidence (monocytes, eosinophils, basophils) were not subjected to statistical analyses.
Interpretation of the results from the statistical analyses was handled in the following manner. The primary comparisons of concern were between the saline control group (group 1) and the bivalirudin-treated groups (groups 3, 4, and 5). If there is a statistically significant difference between the saline control group and a bivalirudin-treated group, a comparison between the vehicle control group (group 2) and the bivalirudin-treated groups (groups 3, 4, and 5) is discussed, as appropriate, to determine if the first difference was due to the vehicle or bivalirudin. If there are no statistically significant differences between the saline control group and the treated groups, any differences between the vehicle control group (group 2) and the treated groups (groups 3, 4, and 5) are not discussed as they are considered spurious.
RESULTS

Clinical Observations and Survival
No bivalirudin-related changes in clinical condition were observed. One saline control group male was found dead on day 13 of the recovery period. There were no notable changes in the clinical condition of this animal prior to death. All other animals survived to the scheduled necropsies. All findings were limited to one or two animals in various groups, occurred similarly in the saline and/or vehicle control groups and/or were findings commonly observed in laboratory rats.
In the toxicokinetic assessment groups, two males and one female in the 500-mg/kg/24 h group and three males and four females in the 2000-mg/kg/24 h group were found dead or euthanized in extremis on the day after blood collection (Table 4) . For all 10 animals, the site of previous blood collection was still seeping. Although not required by the original study design, three of these animals were necropsied (data not presented) but no histologic evaluation was conducted. Necropsy findings were indicative of internal hemorrhage, which is consistent with the pharmacological action of the bivalirudin.
Body Weights and Food Consumption (Toxicology Groups)
Body weights and body weight gains (Table 5 ) were unaffected by bivalirudin infusion. Values for the test article-treated groups were similar to the saline and/or vehicle control group throughout the study. Food consumption was unaffected by bivalirudin infusion, as no remarkable differences from the saline control group values were observed (data not presented). Main study 0/12 0/12 0/12 0/12 0/12 0/12 TK animals 0/10 0/10 2/10 1/10 3/10 4/10
Note. The data are the number of animals found dead or euthanized in extremis over the number of animals in the dose group. Note. Body weights were determined on the days indicated relative to a 24-hour infusion with bivalirudin (i.e., the body weights were determined 6 and 15 days after the completion of the infusion period) and are presented as means ± standard deviations. N = number of rats/sex/group. There were no statistically significant differences.
Clinical Pathology
No bivalirudin-related changes in hematology (Table 6) , clinical chemistry (Table 7) , or urinalysis parameters (selected parameters in Table 7 ) were observed. There were a few isolated instances of statistically significant differences, but these changes were small in magnitude, were not consistently different from both control groups, and/or followed no definitive dose-response trend.
There were no statistically significant effects on clotting action, except on day 1 for females in the 100-mg/kg/24 h and the 2000-mg/kg/24 h groups, that had an APTT value significantly different from that of the vehicle control group. There were also some high values on day 1 in the male 500-mg/kg/24 h and 2000-mg/kg/24 h groups, as indicated by the large standard deviation. Based on the pharmacologic action of bivalirudin, increases in clotting factor times would be expected, but these changes are not large or consistent. Blood samples were collected 3 to 4 hours after the completion of the infusion, which was evidently sufficient time for the active bivalirudin to be cleared from systemic circulation.
Macroscopic Examination
One saline control group male (no. 11082) in the toxicology assessment group was found dead on day 13. Gross necropsy revealed reddened and enlarged adrenal glands and lymph nodes, white areas on the kidneys, and dark red and white areas on the 
Organ Weights
No differences from the saline control group in mean organ weight data (Table 8) day 1 primary necropsy, mean absolute thyroid gland weights and mean thyroid gland weights relative to final body weights were significantly ( p < .01) decreased in all bivalirudin-treated male groups when compared to the saline control group. However, the mean absolute and relative (to final body weight) thyroid gland weights in the vehicle control group males was similar to those observed in bivalirudin-treated male groups, suggesting a vehicle-related effect. At the day 15 recovery necropsy, mean absolute and relative thyroid gland weights in all test article-treated male groups were significantly decreased ( p < .05 or p < .01) when compared to the saline and vehicle control groups. However, no dose relationship was apparent, and there was no bivalirudin-related effect at day 1 from which to recover at day 15. In addition, similar decreases were not observed in the test article-treated female groups. In fact, the mean absolute thyroid gland weight in the 2000-mg/kg/24 h group females was significantly ( p < .05) increased when compared to the saline control group at the day 15 recovery necropsy. Moreover, no microscopic findings in the thyroid were observed to correlate to the clinical findings. Therefore, the decreased thyroid gland weights in the treated male groups were probably a spurious finding.
Microscopic Examination
No bivalirudin-related microscopic changes were observed at the day 1 (primary) or day 15 (recovery) necropsies (Table 9 ). Only organs with findings were presented. The findings for the thyroid were not presented because there were none of any significance. Incidences of intimal hyperplasia, chronic active inflammation, acute vascular inflammation, thrombi, and hemor- rhage were generally similar between the saline control, vehicle control, and test article-treated groups. Chronic granulomatous inflammation observed in the surgical site at the primary and recovery necropsies in both sexes was attributed to the presence of foreign material (i.e., suture) used to stabilize the catheters. At the day 1 primary necropsy, pulmonary granulomatous inflammation with multinucleated giant cells was focally observed in single males in the saline control and 2000-mg/kg/24 h groups and was considered incidental, most likely due to inhalation of foreign material. In the females, the incidence of this finding was 1, 1, and 4 in the 100-, 500-, and 2000-mg/kg/24 h groups, respectively. The lesions were characterized by minimal, focal to random intra-alveolar or intrabronchiolar aggregates of macrophages. The location of the changes was not indicative of a generally distributed test article-related pulmonary effect.
A distinctive pulmonary change was observed in all groups of males and females, including the saline and vehicle control groups, at the day 1 primary necropsy, and was characterized by perivascular/peribronchiolar infiltrates of neutrophils. Incidences were similar between the saline control, vehicle control, and test article-treated groups. At the day 15 recovery necropsy, infiltrates of neutrophils were still present in all groups, with the exception of the 2000-mg/kg/24 h group females. However, the incidence was decreased compared to the primary necropsy. Therefore, pulmonary neutrophil infiltration was not attributed to bivalirudin. Pulmonary emboli were noted at a low incidence at the primary necropsy in the saline control and 2000mg/kg/24 h groups and at the recovery necropsy in the saline control and 500-mg/kg/24 h groups. This finding was probably related to the thrombi observed at the infusion sites and was not related to bivalirudin. Other studies have shown that catheter implantation will result in secondary histopathological changes in the lung (Evans and Kerry 2000) .
